Atea Pharmaceuticals (AVIR) News
NASDAQ: AVIRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
3.96+0.03 (+0.76%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AVIR news summary
We found 7 recent headlines mentioning Atea Pharmaceuticals (AVIR): 0 in the past week and 7 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, AVIR is up 0.76% at $3.96. The most recent story, "Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?", was published by Nasdaq on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Atea Pharmaceuticals headlines
- Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?Here is how Medpace (MEDP) and Atea Pharmaceuticals, Inc. (AVIR) have performed compared to their sector so far this year.NasdaqMEDP, AVIR
- Atea Q3 Loss Narrows On Lower Expenses; Hepatitis C Trial Data Due In Early 2027(RTTNews) - Atea Pharmaceuticals, Inc. (AVIR) reported a narrower third-quarter loss as operating expenses declined. The company expects topline results from its Phase 3 C-FORWARD hepatitis C trial…NasdaqAVIR, HEI.A
- Atea Pharmaceuticals, Inc. Reports Third Quarter 2026 Financial Results and Enters Credit Facility of Up to $200 MillionAtea Pharmaceuticals, Inc. entered into a credit facility agreement with Hercules Capital, Inc. for up to $200 million. Under the agreement, the company drew down $65 million at closing on November…Nasdaq
- Atea Pharma (AVIR) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business UpdatePhase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) InfectionGlobeNewswire
- Atea Secures $200 Mln Credit Facility From Hercules Capital; Shares Up(RTTNews) - On Monday, Atea Pharmaceuticals (AVIR) secured a credit facility of up to $200 million from Hercules Capital (HTGC).NasdaqAVIR, HTGC
- Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral…GlobeNewswire